Archives

Screening, Brief Intervention and Referral to Treatment (SBIRT): An effective approach to identify persons at risk for substance use disorders

Learning Objectives

 

After completing this knowledge-based continuing education activity, pharmacists will be able to

·       Discuss the prevalence and consequences of SUDs
·       Describe the components of SBIRT
·       Recognize motivational interviewing skills to promote readiness to change
·       Discuss harm reduction and how it pertains to SUDs
·       Describe barriers associated with the use of SBIRT in the community setting

After completing this knowledge-based continuing education activity, pharmacy technicians will be able to

·       Discuss the prevalence and consequences of SUDs
·       Describe the components of SBIRT
·       Discuss harm reduction and how it pertains to SUDs
·       Describe barriers associated with the use of SBIRT in the community setting

Image with the word 'Change' in 3D.

Release Date:

Release Date: September 7, 2022

Expiration Date: September 7, 2025

Course Fee

Pharmacists: $7

Pharmacy Technicians: $4

There is no grant funding for this CE activity

ACPE UANs

Pharmacist: 0009-0000-22-051-H08-P

Pharmacy Technician: 0009-0000-22-051-H08-T

Session Codes

Pharmacist: 22YC51-YXT24

Pharmacy Technician: 22YC51-TXY69

Accreditation Hours

2.0 hours of CE

Accreditation Statements

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-22-051-H08-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

 

Disclosure of Discussions of Off-label and Investigational Drug Use

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Faculty

Helen Pervanas, PharmD
Professor of Pharmacy Practice
Massachusetts College of Pharmacy and Health Sciences School of Pharmacy
Worcester/Manchester, MA   

 

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

Dr. Pervanas has no relationship with ineligible companies and therefore has nothing to disclose.

 

ABSTRACT

Hazardous use of alcohol and or opioids can result in harm. If not treated, this hazardous use could develop into a Substance Use Disorder (SUD). SUDs are associated with poor health related outcomes and increased healthcare costs. Screening, brief intervention and referral to treatment (SBIRT), is a public health approach to identify persons with at-risk behaviors and minimize the development of SUDs. The premise behind SBIRT is to promote early intervention with at-risk users and minimize harm. The screening process determines the severity and risk level of a person’s substance use and risk of misuse. Based on the results, healthcare professionals can perform a brief intervention and or a referral to treatment. Healthcare professionals such as pharmacists and pharmacy technicians can use SBIRT to identify and intervene on behalf of persons that are at risk of an SUD. Healthcare providers can perform SBIRT in many healthcare settings including community pharmacies, hospitals, and primary care offices.

CONTENT

Content

Introduction

Substance Use Disorders (SUDs), continue to be a major concern in the United States. In 2017, nearly 20 million people reported an SUD because of alcohol or illicit drug use.1 Costs associated with substance abuse are approximately $249 billion dollars for alcohol and $193 billion dollars for illicit drugs.2-4

 

Alcohol use is second to nicotine for substance use among all substances misused.1 In 2017, 140 million persons aged 12 and older reported alcohol use. A total of 16.7 million reported heavy alcohol use of five or more days over a 30-day timespan. Heavy alcohol use is defined as drinking four or more drinks on one occasion for females and five or more drinks in males. Heavy alcohol use can result in several health-related concerns, to include cirrhosis, depression, cancer, neuropathy, and pancreatitis to name a few.5

 

Typically, clinicians often treat people who have SUDs after they have developed the condition.6,7 Other approaches include inpatient or outpatient treatment programs for those with SUDs and prevention programs to educate and inform the public of the dangers associated with substance use.

An alternative approach to these methods is to identify persons with at-risk behaviors for substance misuse and provide interventions to reduce long-term use and harm. This approach is called SBIRT. SBIRT stands for Screening, Brief Intervention, and Referral to Treatment.7 This evidence-based approach addresses harmful behaviors BEFORE they escalate to a full-blown SUD.

Who can perform SBIRT? 

Many healthcare professionals can perform SBIRT, including doctors, nurses, pharmacists, pharmacy technicians, and behavioral health specialists. SBIRT is also adaptable to a team-based approach. Pharmacists and pharmacy technicians are in a particularly good position to perform SBIRT, as they are accessible, especially in community pharmacy settings.8 SBIRT can also be applied in several clinical settings, such as hospitals and ambulatory care clinics.

SBIRT’s first step involves the screening process. Using a universal screening approach is an important point of the screening process. A universal approach means screening everyone, regardless of who they are, or how they look or act. This makes sense because clinicians cannot determine if someone is using alcohol or other substances based on appearance and behavior. Pharmacists and pharmacy technicians can screen patients in any pharmacy setting to include community, hospital, and ambulatory care. In busy community settings, a targeted approach may be necessary. With targeted approaches, pharmacy teams might screen individuals who are on opioids, benzodiazepines, and other medications that have the potential for abuse. Ideally, however, the universal approach is better. If we focus only on certain populations, we may target individuals who don’t have an SUD and overlook someone who has an SUD but takes no prescription medications. The initial screening question is simple: a single yes/no question that determines if further screening is necessary.

PAUSE AND PONDER: When and where would you use SBIRT in your pharmacy practice?

 

How to Perform SBIRT in a Community Pharmacy Setting

Many pharmacy team members think that they cannot or should not perform SBIRT in their settings. With pharmacy teams expanding their responsibilities, it’s entirely possible to add SBIRT to the community pharmacy tool kit.

Community pharmacy teams need to note that they do not need to perform SBIRT in its entirety. In some cases, pharmacists and technicians may only perform the screening and then refer the patient to a provider for treatment. Pharmacists can perform a brief intervention if opioid misuse is a concern. For example, the pharmacist may access the prescription drug-monitoring program and recognize the patient is seeing multiple providers and using several pharmacies to fill opioid prescriptions. In this case, the pharmacist can perform a screening and brief intervention with the patient to discuss safe opioid use and possible referral to treatment.

Roberta is a 27-year-old female who presents to the pharmacy with a prescription for oxycodone. The pharmacy technician enters the prescription information and notices that Roberta picked up a 30-day supply two weeks ago. The technician informs the pharmacist about the early refill. The pharmacist refers to the prescription drug-monitoring program and notices that Roberta filled two other opioid prescriptions from different doctors at two different pharmacies. The pharmacist screens Roberta and provides a brief intervention.

Pharmacists can refer a patient to treatment or provide information on treatment centers based on the discussion. For example, while engaging with the patient the pharmacist may recognize that the patient is purchasing needles/syringes for illicit drug use. This is a perfect opportunity for the pharmacist to provide a referral to treatment.

 

When screening for alcohol and drugs, healthcare providers use pre-screening questions developed by the National Institute of Alcohol Abuse and Alcoholism for alcohol and the National Institute of Drug Abuse for drugs. Pre-screening questions determine whether additional screenings are necessary.

For alcohol the pre-screening question is, “Do you sometimes drink beer, wine, or other alcoholic beverages?” If the individual answers no, no further screening is necessary. If the individual answers in the affirmative or screens positive for alcohol, the screener would perform additional screening based on the Alcohol Use Disorders Identification Test (AUDIT) to evaluate alcohol use further.9

The same holds true for pre-screening for drug use. If an individual answers in the affirmative to the pre-screening question, “How many times in the past year have you used an illegal drug or a prescription medication for nonmedical reasons?” then the screener would use the Drug Abuse Screening Test (DAST-10) questionnaire to evaluate drug use further.10 (See Figure 1)

Figure 1. DAST-10 Questionnaire10

Image showing the 10 questions that make up the DAST-10

 

Let’s start with the AUDIT questionnaire. This 10-question screening tool addresses recent alcohol use, dependence symptoms, and harmful behaviors. (See Figure 2) Once the screening is complete, the scoring will determine next steps.

Figure 2. AUDIT Questionnaire9

 

Image showing the questions on the AUDIT-10

Some key points to consider when using the AUDIT are the recommended drinking limits and size of the beverage. Did you know that the serving size of a glass of wine is five ounces, and that one bottle of wine typically contains five glasses? A serving of beer is 12 ounces, and a serving of spirits (hard liquor) is one and one-half ounces. The screener should explain serving sizes to the patient to ensure an accurate account of alcohol consumption and score of the AUDIT.

Recommended drinking limits for men are two drinks/day and no more than 14 drinks/week and for women one drink/day and no more than seven drinks/week. For those 65 or older, the recommended limits are similar to women: one drink/day and no more than seven drinks/week.11 Consuming more than the recommended limits can result in binge drinking which is associated with greater harm and dependence. Binge drinking is five or more drinks for men or four or more drinks for women, and people who are 65 or older.12

The AUDIT score determines the severity and next steps that may include a brief intervention or referral to treatment. Individuals scoring between 0 and 7 are low risk and individuals scoring 20 or greater are considered dependent use and would benefit from a referral to treatment.

Pharmacy teams who are familiar with other screening methods may recall that a positive binge drinking finding would require an intervention using those methods. Using the AUDIT, binge drinking alone may not require an intervention. The intervention or referral to treatment would depend on the overall score of the AUDIT.

Scoring the AUDIT

Dependent Use (20+)

Harmful Use (16‒19)

At-Risk Use (8‒15)

Low Risk (0‒7)

 

The screening process for drugs is like that used for alcohol. The DAST-10 questionnaire assesses drug use in the past 12 months. (See Figure 1) Interpretation of the results determines the suggested action. Figure 3 describes screening results and suggested intervention. For example, a score of between 3 and 5 using the DAST-10 suggests harmful use and moderate degree of problems related to drug use.

Scoring the DAST-10

High Risk (6+)

Harmful Use (3‒5)

Hazardous Use (1‒2)

Abstainers (0)

 

Once the screener completes the screening, the score determines next steps for the patient. Next steps could include feedback, brief intervention, and or a referral to treatment. (See Figure 3.) For example, in persons with a low risk, feedback can include discussing the results of screening and risk of harm. A brief intervention is recommended in persons with risky or harmful behavior based on screening results.

Image showing the three categories of screening results and how to intervene for each.

 

Perform a screening for alcohol and drug use using a patient case

Joe is a 32-year-old man who hurt his back three years ago in a car accident. He has used opioids since the accident, but he still complains of pain. He supplements his medications by purchasing additional opioids online and on the street. Joe also has a history of alcohol use. He consumes three to four beers on most days. His family is concerned with his alcohol and drug use and recommends he seek help.

Below are his responses to the AUDIT and DAST-10 questionnaires. Based on his responses to the questions calculate his risk level for alcohol and drug use. See Tables 1 and 2.

Table 1. AUDIT Screening for Joe

Question Answer Score
How often do you have a drink containing alcohol? Daily 4
How many drinks containing alcohol do you have on a typical day when you are drinking? 4 1
How often do you have six or more drinks on one occasion? Once in  awhile 1
How often during the last year have you found that you were not able to stop drinking once you had started? Never 0
How often during the last year have you failed to do what was normally expected of you because of drinking? Monthly 2
How often during the last year have you needed a first drink in the morning to get yourself going after a heavy drinking session? Never 0
How often during the last year have you had a feeling of guilt or remorse after drinking? Never 0
How often during the last year have you been unable to remember what happened the night before because of your drinking? Never 0
Have you or someone else been injured because of your drinking? No 0
Has a relative, friend, doctor, or other health care worker been concerned about your drinking or suggested you cut down? Yes 4

 

Total Score 12

 

Based on Joe’s responses to the AUDIT what is his score and risk level?

Based on his responses to the questions Joe scored 12 on the AUDIT, which puts him as at-risk-use.

 

 

Table 2. DAST-10 Screening for Joe

 

Question Answer Score
Have you used drugs other than those required for medical reasons? Yes 1
Do you abuse more than one drug at a time? No 0
Are you unable to stop using drugs when you want to? Yes– The pain gets too great 1
Have you ever had blackouts or flashbacks as a result of drug use? No 0
Do you ever feel bad or guilty about your drug use? No 0
Does your spouse (or parents) ever complain about your involvement with drugs? Yes 1
Have you neglected your family because of your use of drugs? No 0
Have you engaged in illegal activities in order to obtain drugs? Yes 1
Have you ever experienced withdrawal symptoms (felt sick) when you stopped taking drugs? Yes 1
Have you had medical problems as a result of your drug use (e.g., memory loss, hepatitis, convulsions, bleeding)? No 0
Total Score 5

 

Based on Joe’s responses to the DAST-10 what is his score and risk level?

Based on his responses to the questions Joe scored a five, which indicates harmful use. We will come back to Joe and determine next steps for him.

Summary of screening

  • Screening is an important first step to determine the severity and risk level of substance use
  • Use a universal screening approach
  • Determine the level of risk and intervention based on screening results
  • Pharmacists and pharmacy technicians can successfully perform screenings

Brief Intervention (BI)

Following the screening process and based on the results, a BI may be necessary. A brief intervention, also referred to as a brief negotiated interview (BNI), can be performed by a healthcare professional such as a pharmacist, doctor, nurse, or behavioral specialist. Addiction experts recommend using a BNI for those with “at risk” or harmful level of risk based on screening results. During the BNI, the healthcare professional uses motivational interviewing (MI) to have a conversation with the patient and evoke the patient’s personal motivation for change.13 Before we talk more about BNIs, let’s talk about the five stages of change.14 Change happens gradually, and individuals can move through the different stages depending on the situation and can move in and out of the different stages. In pre-contemplation, individuals may not be ready to make a change. Figure 4 depicts the five stages of change.

Figure 4. Stages of Change14

Image showing the 4 stages of change

MI has several components, which can be overwhelming and confusing. Here is a brief outline of the components.

Components of MI

  • Key qualities of MI
  • Basic Principles of MI
  • BNI Process
  • OARS Framework

What is a brief intervention’s purpose and how do we use MI to evoke change? Motivational interviewing is an evidence-based approach to changing behaviors.13,15

Key qualities of MI include13

  • Facilitate communication between the healthcare professional and patient, where information and guidance is given
  • Empower individuals to change based on what’s important to them
  • Respect patient’s autonomy to facilitate change

Healthcare professionals can use MI to engage the patient as an equal partner. Although the name motivational interviewing suggests the healthcare professional is motivating the patient, that isn’t the case. MI is not a way to change individuals, make demands of patient, or instruct them what to do or not do. MI is a way to help examine situations and options for patients. MI is not easy to learn and takes practice. Pharmacists may find MI difficult to apply because counseling and instructing patients is part of everyday practice. MI is different and recognizes that patients are responsible for their actions and taking action to make changes.

MI can be very useful when people

  • Have mixed feelings or are ambivalent about change
  • Have low confidence about making changes
  • May be uncertain about whether they want to make changes, creating low desire
  • Are not clear about the benefits of change and concerns related to the current situation, so do not deem change important

MI is based on four basic principles15,16:

  • Express empathy
  • Develop discrepancy
  • Roll with resistance
  • Support self-efficacy

Expressing empathy is an important first step of the MI process. You do this by seeking to understand how the person feels without judgement. (See Side Bar-tips to express empathy)

 

Side Bar: Tips to Express Empathy

  • Maintain eye contact but avoid staring
  • Use reflective listening to hear and understand and repeat back the information
  • Avoid sympathy, “I’m sorry this happened to you”
  • Ask clarifying questions
  • Avoid passing judgement

 

Developing discrepancy

Using this principle, the provider discusses the discrepancy between the patient’s values and behavior. This involves discussing the good and the bad related to the behavior. Most patients are aware of the dangers related to substance misuse but are ambivalent about making a change. Discrepancy between the patient’s goals and current behavior motivates change.

Roll with resistance

During the BNI, patients may become defensive when talking about their substance use. This resistance is often because of a fear to change. To decrease resistance, the healthcare professional can redirect the discussion for the patient to understand the harm associated with the behavior. Last, the provider can explore the pros and cons of the patient’s behaviors. For example, a patient may enjoy the euphoria of heroin use (pro) but conversely contracts a cellulitis infection (con).

Support self-efficacy

This guiding principle focuses on supporting patient goals. Patients may feel that they cannot meet goals or expectations. It is important that the provider believe in the patient and promote confidence to support change.

Here is an example of a brief intervention.

Cynthia is at the pharmacy having a discussion with the pharmacist. She is concerned about her alcohol use. The pharmacy technician performs the AUDIT screening and provides the results to the pharmacist for discussion. AUDIT Score: 15 “At-risk use”

Cynthia: “I have been drinking more often over the last few months.”

Pharmacist: “Tell me more about that, Cynthia.” (Reflective listening)

Cynthia: “Work has been very stressful, and alcohol helps me relax. I used to drink only socially on the weekends with friends but now I drink almost every day. My teenage daughter sees me drink every night and she tells me I should stop because it’s not good for me. I don’t want to be a bad role model for her.”

Pharmacist: “So you are saying that you drink alcohol almost every day so that you can cope with the stress at work?” (Reflective listening)

Cynthia: “Yes. I am using alcohol to cope with stress at work.”

As you can see by the conversation above, the pharmacist reflects on Cynthia’s concerns regarding stress and work, which cause her to drink alcohol to cope. The pharmacist makes no judgement on whether the behavior is bad or that she should stop drinking. The pharmacist applies reflective listening and expresses empathy.

Developing discrepancy looks at current behaviors versus future goals. Let’s continue the conversation with Cynthia and apply this principle.

Pharmacist: “It sounds like you are having a hard time at work. But you also love your daughter and want to be a good role model for her. Is that right?” (Developing discrepancy)

Here the pharmacist emphasizes Cynthia’s concerns with her alcohol use and how that affects her daughter. This is the discrepancy. This allows Cynthia to recognize the pros and cons of her alcohol use so that she may change her behavior.

In roll with resistance, patients may pushback stating that they don’t have a problem, or their drinking or drug use is not a problem. In this case, it may require further discussion of current behavior and negative effects related to that behavior. The correlation of cause and effect can motivate the patient to change.

Last, support self-efficacy, where patients are responsible for deciding on actions they will make to support change. This is important because patients take the responsibility of making changes.

Regardless of the stage, MI encourages the patient to express the desire to change or what is referred to as “change talk.” In change talk, look at the following: desire, ability, reasons and need or acronym DARN. See the example below based on the conversation with Cynthia earlier.

Desire: “I need to drink less alcohol.”

Ability: “I could find healthier ways of coping with the stress at work, like yoga or meditation.”

Reasons: “I want my daughter to be proud of me.”

Need: “I might lose my daughter.”

 

This “change talk” can prepare the individual to make changes and act on those changes. As mentioned earlier, MI is a collaborative approach between the patient and healthcare professional providing the brief negotiated interview and involves four fundamental processes. Let’s talk about each of the processes.

  1. Engage
  2. Focus
  3. Evoke
  4. Plan

 

Engage

Having an honest and open conversation that engages the patient is the first step in the process. Listening without passing judgement or trying to fix the problem is important. The OARS framework includes interactive techniques to engage the patient. OARS stands for open questions, affirmations, reflections, and summaries. Table 3 describes each element of the framework and purpose.

Table 3. OARS framework15

Interview Skill Description Purpose
Open-ended questions Ask the patient open-ended question vs. yes or no

 

Builds trust

Gathers information

Affirmations Show empathy for the patient

Acknowledge the patient’s ability to make a change in their life

Emphasize key points that are important to the patient.

 

Discuss/encourage patient’s abilities and healthy behaviors

Build the patient’s confidence and self-efficacy

Reflections Listen and understand what the patient is saying and repeating back to the patient Repeat back what was said

Incorporate unspoken feelings thoughts or behaviors

Summaries Review key points of the conversation

Use reflective listening

Help the patient see the big picture

Create an action plan

Emphasize key points of the conversation

 

 

Focus

During the conversation, focus on guiding patients to identify behaviors they struggle with or ambivalent to make a change. During the conversation, understand the patient’s dilemma or ambivalence. Asking what is important to them can help to identify the target and behavior that may inhibit them from reaching their goals.

Evoke

During the evoke process, we want patients to discuss their reasons for change and incorporate “change talk” during the conversation. Let’s go back to the conversation with Cynthia. Cynthia recognizes that she drinks alcohol to cope with the stress at work. She is also concerned that her drinking upsets her daughter and Cynthia wants to be a good role model. Her reason for change is that she wants to be a good role model for her daughter. Changing her behavior for her daughter is important to her.

Plan

The patient would commit to a plan of action that is simple, realistic, specific, and attainable. The patient should also set a timeline for the plan.

The incorporation of core skills is fundamental to MI. The acronym OARS, involves four interviewing skills to enhance motivation for change.15

Asking open-ended questions allows patients to provide more information and can provide insight to their feelings and thoughts. Close-ended questions only elicit a yes or no response with no further details. Here is an example of an open-ended versus close-ended question.

  • Close-ended question: Do you drink alcohol often?
  • Open-ended question: How much alcohol do you drink per week?

Affirmations

Statements of affirmation acknowledge the patient’s ability to make a change. Statements by the provider emphasize key points most important to the patient and support the patient to make changes.

Reflections

Reflections involve listening and understanding what the patient is saying. This can be as simple as repeating back the patient’s statements and incorporating the patient’s unspoken feelings or intent. Furthermore, reflections confirm with the patient that what you are repeating back is accurate. An example might be saying, “I heard you say that you have tried to stop drinking in the past and you have not been able to do it and I sense you are frustrated. Is that correct?” The latter statement incorporates the patient’s unspoken feelings and confirms an accurate account of the reflection.

PAUSE AND PONDER: Along the substance use continuum, with whom would you negotiate a reduction in use to lower risk levels?

Performing a BNI

A BNI uses MI to raise awareness in patients with risky or harmful substance use. Here are four important steps to follow when conducting a BNI.

Build rapport-raise the subject

Open the conversation by beginning with a general conversation and ask permission to discuss the topic of substance use. For example, you could say: “Thank you for meeting with me today. Would you mind speaking with me? Could I ask you some questions about your substance use?”

This engages the patient in the conversation. The conversation could highlight the patient’s substance use and explore the pros and cons of the situation. For example, with Cynthia, her alcohol use allows her to cope with stress at work. Conversely, her alcohol use makes her daughter upset and she wants to be a good role model for her. During the BNI, the provider should use open-ended questions to allow the patient to provide more information and further explore the patient’s substance use. Incorporating reflective listening, summarizing what the patient says, and weighing the pros and cons allows for decisional balance.

Provide feedback

After listening to the patient ask permission again to offer feedback based on the conversation. Review the screening results with the patient and connect consequences to substance use. Here is an example.

Karla is a 32-year-old mother of three children. She and her children are in the emergency department because of a car accident. Karla’s alcohol level is 0.09.  (Blood alcohol levels ≥ 0.08% = legally impaired)

You perform a screening on Karla using the AUDIT. Her score reveals harmful use and when asked about her alcohol use causing injury, she states in the affirmative that she was under the influence of alcohol while driving with her children and feels extremely guilty and upset. During the conversation you ask permission to speak to Karla about her alcohol use and how this may be a direct cause of the accident. Karla may recognize the impact of her alcohol use and change her behavior.

Build readiness to change

Here we ask if they may be willing to make some changes. When doing so we can ask how willing they are or how ready they are to make a change. The provider can use a visual tool to assess willingness to change. This visual tool is a readiness ruler. (See Figure 5.) When approaching the patient, clinicians can use the readiness ruler in a way similar to that of a pain scale. For example, “On scale of 1 to 10, where 1 means you are not at all ready to change to 10 meaning you are very or completely ready to change. How ready are you to make a change about your substance use?”

Figure 5. Readiness Ruler15

Image showing a 'readiness' ruler, with marks from 0 to 10.

PAUSE AND PONDER: What would be your response to a patient that states they are a 3 on the readiness ruler?

Negotiate a plan for change

Based on the screening results, the plan can vary. It may involve reducing risky use of substances and or a referral to treatment. The plan should be simple, realistic, specific, and attainable. Following up with patients to discuss changes and reinforcing the plan for change will promote long-term success.

Referral to Treatment

Patients diagnosed with an SUD by a provider or who have behaviors that are substance dependent (e.g., substance related injuries or inability to stop) or high-risk, such as increased frequency of substance use, require treatment. Healthcare professionals can easily refer the patient to treatment. Initiating the referral process by calling a trained treatment specialist on behalf of the patient to schedule an appointment can better assist the patient. Many resources are available to find treatment centers for patients. SAMHSA’s National Treatment Facility Locator is a helpful resource to locate a treatment center:17 http://findtreatment.samhsa.gov. Treatment options include counseling, medication assisted treatment, complimentary wellness, and support groups. The level of care is individualized and based on the severity of the substance use and comorbidities.

Key points for referral to treatment

  • Make a plan with the patient
  • Use a warm handoff
  • Decide how you will communicate with the provider
  • Confirm the plan with the patient

A warm handoff involves personally introducing the patient to the treatment provider. This helps build rapport and trust and increases the patient’s willingness to schedule an appointment. Warm handoffs are also more successful than passive referrals.

SBIRT in Practice

Healthcare professionals can utilize SBIRT in many areas of practice. Pharmacists and pharmacy technicians are one of the most accessible healthcare professionals, especially in community pharmacy settings. In this setting, pharmacists and pharmacy technicians can meet with patients to perform screenings, conduct a BNI, or refer to treatment, with the ultimate goal of reducing the risk of an SUD and patient harm.

Harm reduction is key to help to minimize adverse effects related to substance use.18 Harm reduction involves policies, programs, and practices that focus on the individual’s human rights. The goal of harm reduction is to keep people safe. Providers can reinforce positive changes in patients using MI. Examples of harm reduction include drug take back programs, access to naloxone, and syringe distribution.18 Distributing clean needles/syringes not only reduces harm for the persons using them but also contributes to community safety by reducing the spread of HIV, hepatitis, and other blood borne diseases.

Sadly, in community pharmacy settings, several barriers exist. Some include lack of privacy, lack of staffing, lack of time, and stigmas.19, 20   A stigma is an inaccurate belief against individuals based on a specific characteristic, race, or nation of people.22,23 Often, we see this in patients with a mental illness. Stigma towards individuals with SUDs also exist and are one of the most challenging barriers because of a misconception that an SUD is not a disease or medical condition and individuals with an SUD are at fault.23 You may hear people say, “They don’t want to get better” or “I don’t want those kinds of people in my pharmacy.” Stigmas can impede care and harm the patient.

It is important to recognize that an SUD is a medical condition and requires treatment. Stigmatizing language like “addict” or “junkie” has a negative connotation and can lead to barriers in care. Avoid using stigmatizing language. For example, an addiction is an SUD. Clinicians need to replace the words “addict” or “junkie” with the words “person with an SUD.” This recognizes the disease and not the person with the SUD.

Patient case Joe and brief intervention.

Joe is a 32-year-old man who hurt his back three years ago in a car accident. He has used opioids since the accident, but he still complains of pain. He supplements his medications by purchasing additional opioids online and on the street. Joe also has a history of alcohol use. He consumes three to four beers on most days. His family is concerned with his alcohol and drug use and recommends he seek help.

AUDIT score: 12-At risk use

DAST-10 score: 5-Harmful use

What recommendations are appropriate based on the screening results?

Joe’s alcohol screening score of 12 shows that he is at risk use and his DAST-10 score of 5 shows that his use of drugs is harmful. In Joe’s case, he would benefit from a brief intervention and referral to treatment.

A brief intervention would be helpful for Joe. Here is an example of an intervention between Joe and the pharmacist at the ambulatory care clinic.

Pharmacist: “Good morning, Joe. Would it be OK if I speak with you for a few minutes about your screening results that you took earlier?”

Joe: “I guess that would okay.”

Pharmacist: “Based on your screening results, your alcohol use puts you at risk for harm and your drug use is possibly already harmful for your health and for those around you.”

Joe: “I don’t know what you are talking about. I don’t have a problem.”

Pharmacist: “Let me ask you this. From your perspective what is your relationship with alcohol and drugs?”

Joe: “Well I guess I do drink every day and I am on oxycodone for the pain. I was in an accident a few years ago and the pain won’t go away. I need the oxy. My family thinks I need help.”

Pharmacist: “Thank you for opening up to me and telling me how you feel after your accident and that you’re still in pain. Tell me some of the things that are good about your alcohol and drug use and some things that are not good?”

Joe: “Well alcohol helps me forget about my problems for little bit. The drugs help my pain, but I feel guilty sometimes because I buy it off the street because my doctor won’t give me enough.”

Pharmacist: “What is it about your drug use that makes you feel guilty?”

Joe: “My family means a lot to me, and I am afraid that my wife might leave me and take the kids.”

Pharmacist: “It sounds like you love your family. What changes do you think you could make about your alcohol and drug use?”

Joe: “Well I guess I could cut back on my drinking and find some other ways to deal with my stress. I rely too much on the oxy so I don’t think I could cut back on that right now.”

Pharmacist: “That’s great that you are willing to cut back on your alcohol use. Tell me what that would look like?”

Joe: “I think I could limit myself to three beers a day instead of four or five. I can start there and see how it goes.”

Pharmacist: “That’s a great start. On a scale of 1-10 where 1 means that you are not at all ready to make this change and 10 meaning that you are completely ready where do you think you would put yourself on this scale?”

Joe: “I guess I would rate myself as being a 7.”

Pharmacist: “Joe, that’s great. A 7 is very close to being completely ready to make this change. Can I ask you what is holding you back from you being at a 10?

Joe: “I don’t think that I am completely ready to make a change. I am also afraid of failing.”

Pharmacist: That is a valid fear. Speaking with someone about your alcohol use and treatment can really help. Would you be willing to meet Dr. Smith here at the office and set up an appointment with him?”

Joe: “Sure. I could meet him now while I am at the clinic.”

The pharmacist walks Joe down the hall to meet Dr. Smith who is a behavioral specialist focusing on SUDs. The pharmacist performs a warm handoff, introducing Joe to Dr. Smith.

The pharmacist engaged Joe in the conversation and reflected on what Joe said and felt. During the conversation, the pharmacist asked open-ended questions to gain more insight into Joe’s alcohol and drug use and discussed his readiness to make a change. Joe rated himself as a 7 on the readiness scale. Discussing where they are on the readiness ruler can determine patients’ willingness to change, possible resistance, and potential fears. Joe recognized the pros and cons of his alcohol and drug use and made a plan to decrease his alcohol use and meet with a behavioral specialist about his drug use.

Conclusion

SBIRT is a public health approach to intervene with individuals at risk of an SUD. SBIRT is effective in reducing alcohol use by 40% and illicit drug use by 76%.24 Applying universal screening and promoting change to reduce high-risk behavior before it escalates to an SUD can greatly reduce patient harm and minimize healthcare costs.

Depending on the setting, time constraints, day-to-day workload, and staffing, SBIRT may be a challenge to perform.  Pharmacists and pharmacy technicians should be knowledgeable about SBIRT and treat persons with SUDs, where feasible, in a professional, caring manner. SBIRT can be a useful approach to identify those with at risk behaviors and apply early intervention methods to minimize harm and development of an SUD.

Pharmacist Post Test (for viewing only)

SBIRT Exam Questions
Pharmacist
After completing this continuing education activity, pharmacists will be able to
1. Discuss the prevalence and consequences of SUDs
2. Describe the components of SBIRT
3. Recognize motivational interviewing skills to promote readiness to change
4. Discuss harm reduction and how it pertains to SUDs
5. Describe barriers associated with the use of SBIRT in the community setting

1. SBIRT is a public health approach to identify persons at risk of a substance use disorder. For the acronym SBIRT, what does BI stand for?
A. Brief Interaction
B. Brief Intervention
C. Brief Intermediation

2. In the U.S., which of the following substances is most abused?
A. Nicotine
B. Alcohol
C. Oxycodone

3. Which of the following is used to screen for alcohol use?
A. AUDIT
B. DAST
C. ADST

4. Jim, a 42-year-old man, completed the alcohol screening questionnaire and scored 17. How would you rate his alcohol use?
A. At-risk use
B. Harmful use
C. Dependent use

Use patient case Sean for questions 5-7.
Sean is 42-year-old male who presents to the emergency department after a car accident. He scores 14 on the AUDIT questionnaire and the pharmacist performs a BNI. He has not worked since COVID and drinks to forget about his problems. The pharmacist discusses Sean’s drinking habits and related harm. Sean is defensive and states that he does not have a drinking problem.

5. Which of the following is an appropriate response to Sean’s statement, that he does not have a drinking problem?
A. “It seems to me you have a drinking problem. That’s how you ended up in the hospital.”
B. “You need to stop drinking or this will happen again. I’ve seen it time and time again.”
C. “Can we talk more about how you ended up in the emergency department today?”

6. The pharmacist reflects on Sean’s statements. Which is one of the following is example of reflective listening?
A. “Let’s create an action plan to decrease your alcohol use so you can have some goals to accomplish.”
B. “ I know that you don’t want to be here today, but can you see how important it is?”
C. “Thank you for sharing how you feel about losing your job. That must be hard for you.”

7. The pharmacist wants more information about Sean’s motivation to change behavior. Which of the following promotes the BEST response?
A. “Are you willing to cut back on your alcohol use?”
B. “What are some negative effects of your alcohol use?”
C. “Do you think your alcohol use contributed to the car accident?”
8. Fill in the blank. Harm reduction involves policies, programs, and practices to focus on the individual’s ________ ________.
A. Substance Use
B. Harmful Behaviors
C. Human Rights

9. Which of the following is an example of non-stigmatizing language?
A. He has a substance use disorder
B. He is addicted to drugs
C. He is heroin junkie

10. Which of the following is a barrier to providing SBIRT in a community pharmacy setting?
A. Cost of screening
B. Safety
C. Stigmas

Pharmacy Technician Post Test (for viewing only)

Pharmacy Technician Post-test
After completing this continuing education activity, pharmacist technicians will be able to
1. Discuss the prevalence and consequences of SUDs
2. Describe the components of SBIRT
3. Discuss harm reduction and how it pertains to SUDs
4. Describe barriers associated with the use of SBIRT in the community setting

1. SBIRT is a public health approach to identify persons at risk of a substance use disorder. For the acronym SBIRT, what does BI stand for?
A. Brief Interaction
B. Brief Intervention
C. Brief Intermediation

2. In the U.S., which of the following substances is most abused?
A. Nicotine
B. Alcohol
C. Oxycodone

3. Which of the following is used to screen for alcohol use?
A. AUDIT
B. DAST
C. ADST

4. Which of the following is an example of non-stigmatizing language?
A. He has a substance use disorder
B. He is addicted to drugs
C. He wants to be a junkie

5. Which of the following is associated with the distribution of clean needles/syringes?
A. Reduction of blood borne diseases
B. Increase in illicit drug use
C. Increase in drug overdoses

6. What are the recommended alcohol drinking limits for men who are younger than 65 years?
A. No more than 1 drink per day and no more than 7 drinks per week
B. No more than 2 drinks per day and no more 14 drinks per week
C. No more than 4 drinks per day and no more than 14 drinks per week

7. Which of the following is used to screen for drug use?
A. AUDIT
B. DAST
C. ADST

8. What is the goal of harm reduction?
A. Keeping people safe
B. Stopping drug use
C. Giving people free needles

9. Which of the following is a barrier to providing care to those with a SUD in a community pharmacy setting?
A. Cost of screening
B. Safety
C. Stigmas

10. SBIRT is effective in reducing alcohol use by___ %
A. 40%
B. 76%
C. 20%

References

Full List of References

References

     
    1. Substance abuse and mental health services administration. 2017 NSDUH annual national report. Accessed June 9, 2021. Available at https://www.samhsa.gov/data/report/2017-nsduh-annual-national-report
    2. Centers for Disease Control and Prevention. Excessive Drinking is Draining the U.S. Economy. Updated December 2019. Accessed June 21, 2021. https://www.cdc.gov/features/costsofdrinking/
    3. National Drug Intelligence Center. National Drug Threat Assessment. Washington, DC: United States Department of Justice; 2011. Accessed June 21, 2021. www.justice.gov/archive/ndic/pubs44/44849/44849p.pdf
    4. Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL. Societal Costs of Prescription Opioid Abuse, Dependence, and Misuse in the United States. Pain Medicine. 2011; 12:657-667.
    5. Rehm J, Room R, Graham K, et al. The relationship of average volume of alcohol consumption and patterns of drinking to burden of disease: An overview. Addiction. 2003; b;98(9):1209–1228.
    6. Institute of Medicine (IOM). Broadening the base of treatment for alcohol problems. Washington, DC: National Academies Press; 1990.
    7. Babor TF, McRee BG, Kassebaum PA, Grimaldi PL, Ahmed K, Bray J. Screening, Brief Intervention, and Referral to Treatment (SBIRT). Subst Abuse. 2007;28(3):7–30.
    8. Shonesy BC, Williams D, Simmons D, Dorval E, Gitlow S, Gustin RM. Screening, Brief Intervention, and Referral to Treatment (SBIRT) in a retail pharmacy setting: The pharmacist’s role in identifying and addressing risk of substance use disorder. J Addict Med. 2019; 13(5):403-407.
    9. WHO screening and AUDIT. Accessed June 9, 2021. http://www.who.int/substance_abuse/activities/sbi/en/
    10. Smith PC, Schmidt SM, Allensworth-Davies D eta. A single-question screening test for drug use in primary care. Arch Intern Med. 2010; 170(13):1155−1160.
    11. Centers for Disease Control and Prevention. Alcohol use and your health. Accessed June 9, 2021. Available at: http://www.cdc.gov/alcohol/fact-sheets/alcohol-use.htm
    12. National Institute of Alcohol Abuse and Alcoholism (NIAAA) for alcohol. Accessed June 9, 2021. Available at https://www.rethinkingdrinking.niaaa.nih.gov/how-much-is-too-much/is-your-drinking-pattern-risky/Drinking-Levels.aspx.
    13. Miller WR, Moyers TB. Motivational Interviewing and the clinical science of Carl Rogers. J Consult Clin Psychol. 2017; 85(8):757-766. doi: 10.1037/ccp0000179.
    14. Prochaska JO, Velicer WF, Rossi JS, et al. Stages of change and decisional balance for 12 problem behaviors. Health Psychol. 1994;13:39–46.
    15. Miller WR, Rollnick S. Motivational Interviewing: Helping people to change (3rd Edition). Guilford Press; 2013.
    16. Miller WR, Zweben A, DiClemente CC, Rychtarik RG. Motivational enhancement therapy manual: A clinical research guide for therapists treating individuals with alcohol abuse and dependence. Rockville, MD: National Institute on Alcohol Abuse and Alcoholism. Accessed June 9, 2021. Available at https://www.motivationalinterviewing.org/sites/default/files/MATCH.pdf
    17. Substance Abuse and Mental Health Services Administration. Behavioral health treatment services. Accessed August 2, 2021. Available at https://findtreatment.samhsa.gov/
    18. Harm reduction international. Accessed July 7, 2021. Available at https://www.hri.global/what-is-harm-reduction.
    19. Hawk KF, Vaca FE, D'Onofrio G. Reducing fatal opioid overdose: Prevention, treatment and harm reduction strategies. Yale J of Biol and Med 2015;88(3):235–245.
    20. Werremeyer A, Mosher S, Eukel H, et al. Pharmacists’ stigma toward patients engaged in opioid misuse: When “social distance” does not mean disease prevention. [published online ahead of print, 2021 March 22]. Subst Abuse. 2021;Mar 22; 1-8. doi: 10.1080/08897077.2021.1900988
    21. Murphy A, Phelan H, Haslam S, Martin-Misener R, Kutcher SP, Gardner DM. Community pharmacists’ experiences in mental illness and addictions care: a qualitative study. Subst Abuse Treat, Prev, and Policy. 2016; 11:6 DOI 10.1186/s13011-016-0050-
    22. Caddell J, Gans S. Verywellmind. What is stigma? Accessed August 5, 2021. Available at https://www.verywellmind.com/mental-illness-and-stigma-2337677
    23. Fernandez L. Addiction or Substance Use Disorder? How Using the Right Language Helps Fight Stigma. Accessed August 12, 2021. Available at https://illuminaterecovery.com/blog/substance-use-disorder-stigma/
    24. Aldridge A, Linford R, Bray J. Substance use outcomes of patients served by a large US implementation of Screening, Brief Intervention and Referral to Treatment (SBIRT). Addiction. 2017; Feb; 112 (Suppl. 2), 43–53 doi: 10.1111/add.13651.

    Arthur E. Schwarting Symposium LIVE Event 2026 – TBD

    The Arthur E. Schwarting Symposium is an educational conference focused on pharmacy practice for pharmacists in many settings.

    Arthur E. Schwarting Symposium 2026

    Five hours of live CE

    REGISTER NOW

    2025 Schwarting Agenda

    11:00am-12:00 pm  Information overload to action: Decoding academic concepts for pharmacy preceptors
    Jennifer Luciano, PharmD, Director Office of Experiential Education, University of Connecticut School of Pharmacy, Storrs, CT

    At the end of this presentation the learner will:

    • Discuss how ACPE standards, the NAPLEX blueprint, and Entrustable Professional Activities (EPAs) guide the development of clinical competence in students, specifically in the context of patient care.
    • Describe the Pharmacist Patient Care Process (PPCP) and its key components.
    • Explain how the PPCP framework is applied in experiential education and clinical rotations.

    ACPE UAN: 0009-0000-25-026-L04-P                                     Application

    12:05-1:05 pm   Patient Safety: Anticoagulation Stewardship: Identifying Key Data, Avoiding Errors, and Enhancing Safety
    Youssef Bessada, PharmD, BCPS, BCPP, Assistant Clinical Professor,UConn School of Pharmacy, Storrs, CT

    At the end of this presentation the learner will:

    • Differentiate high-priority, practice-changing information from less relevant or conflicting data after reviewing the anticoagulation guidelines, literature and clinical updates.
    • Recognize common anticoagulation-related errors in pharmacy practice and implement strategies to minimize patient safety risks
    • Identify red flag situations in anticoagulation management that pose patient safety risks.
    • Determine the appropriate guidelines or evidence-based resources to guide clinical decision-making and referrals

    ACPE UAN: 0009-0000-25-029-L05-P             Application

    1:10-2:10 pm  Information Overload in Chronic Coronary Disease
    Michael White, PharmD, FCCP, FCP, BOT Distinguished Professor and Chair of Pharmacy Practice University of Connecticut School of Pharmacy, Storrs, CT

    At the end of this presentation the learner will:

    • Determine if a patient has chronic cardiac disease (CCD).
    • Identify lifestyle modifications that can reduce the risk of CCD.
    • Identify therapies that can reduce final health outcomes for specific CCD patient types to design successful drug regimens.
    • Describe how the steps in the PPCP process can be applied when reviewing a cardiac patient.

    ACPE UAN:  0009-0000-25-028-L01-P            Application

    2:15-3:15 pm Law: Understanding Disabled Pharmacy Patients’ Right to Nondiscrimination
    Caroline Wick, JD, MSPH, BA, Practitioner-in-Residence and Acting Director of the Disability Rights Law Clinic, American University Washington College of Law, Washington DC 

    At the end of this presentation the learner will:

    • Describe the federal and state laws that protect patients with disabilities
    • Recognize situations in which accommodations should be provided to disabled patients
    • Recall examples of common modifications for patients with disabilities

    ACPE UAN: 0009-0000-25-027-L03-P            Knowledge

    3:20-4:20 pm- So Much STI Data: Information to help you stay current and informed
    Jennifer Girotto, PharmD, BCPPS, BCIDP, Associate Clinical Professor, UConn School of Pharmacy, Storrs, CT

    At the end of this presentation the learner will

    • Describe updated screening recommendations and epidemiological trends of sexually transmitted infections (STIs).
    • Review the Centers for Disease Control and Prevention’s STIs recommendations.
    • Explain latest evidence based STI updates.
    • Given medication shortages, outline the pharmacist’s role in delivering targeted patient education and implementing strategies for responsible medication stewardship for STIs.

    ACPE UAN: 0009-0000-25-030-L01-P             Application

     

    Handouts will be posted 72 hours prior to the event  in 2 slide/page and 6 slide/page below:

    11:00am-12:00 pm    Information overload to action: Decoding academic concepts for pharmacy preceptors     2 slides/page
                                             Information overload to action: Decoding academic concepts for pharmacy preceptors     6 slides/page

    12:05-1:05 pm           Patient Safety: Anticoagulation Stewardship: Identifying Key Data, Avoiding Errors, and Enhancing Safety   2 slides/page
                                             Patient Safety: Anticoagulation Stewardship: Identifying Key Data, Avoiding Errors, and Enhancing Safety     6 slides/page

    1:10-2:10 pm         Information Overload in Chronic Coronary Disease2 slides/page
                                       Information Overload in Chronic Coronary Disease6 slides/page

    2:15-3:15 pm          Law: Understanding Disabled Pharmacy Patients’ Right to Nondiscrimination 2 slides/page
                                        Law: Understanding Disabled Pharmacy Patients’ Right to Nondiscrimination 6 slides/page                 

    3:20-4:20 pm     So Much STI Data: Information to help you stay current and informed2 slides/page
                                    So Much STI Data: Information to help you stay current and informed 6 slides/page

    ACPE Logo“The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.”

     

     

     

    Henry A. Palmer CE Finale LIVE Event Friday, Dec 13, 2024

    Photograph of Henry A. Palmer

    The School of Pharmacy Henry A. Palmer CE Finale, named for beloved professor and mentor, Dr. Henry A. Palmer, is a continuing education program offered at the end of each calendar year. Held during December, the program helps pharmacists fulfill their last minute CE requirements. The program is typically not a single theme, but an ala carte program offering a variety of presentations covering contemporary issues in pharmacy practice/therapeutics. Pharmacists may enroll in one or more [up to 8] hours of continuing education.

    The University of Connecticut

    School of Pharmacy

    Presents the

    Henry A. Palmer C.E. FINALE 2024

    Aged to Perfection: Pharmacist Strategies for Elder Care Excellence

    A LIVE (both virtual and in-person) application and knowledge-based continuing education activity for practicing pharmacists in all settings

     

    Friday, December 13, 2024

    7:30 AM 5:00 PM Eastern Time
    Sheraton Hartford South,
    Rocky Hill, CT

    For a full course description see the Henry A. Palmer CE Finale Brochure 2024

    REGISTRATION

    Handouts for CE Finale will be available the first week of December

    HANDOUTS FOR CE FINALE (these will be uploaded as available)

    LAW: Medical-Legal Considerations of Aging Patients for Pharmacists-1 slide per page and clickable links

    Law: Seniors Self-Diagnosing and Treating: A Brave (and scary) New World-6 per page
    Law: Seniors Self-Diagnosing and Treating: A Brave (and scary) New World
    -2 per page

    Balancing Safety and Efficacy: Addressing Medication Dilemmas in Older Adults -6 per page
    Balancing Safety and Efficacy: Addressing Medication Dilemmas in Older Adults
    -2 per page

    Immunization: Our Best Shot – Tips and Tools to Vaccinate Older Adults-6 per page
    Immunization: Our Best Shot – Tips and Tools to Vaccinate Older Adults
    2 per page

    Opioids: Impact of Palliative Care on Total Pain in the Older Adult-6 per page
    Opioids: Impact of Palliative Care on Total Pain in the Older Adult
    2 per page

    Patient Safety: Cheers to the Beers: Unpacking the Latest Updates for Safer Prescribing-6 per page
    Patient Safety: Cheers to the Beers: Unpacking the Latest Updates for Safer Prescribing
    -2 per page

    Beyond Memory Loss: Mastering the Management of Behavioral Symptoms in Dementia6 per page
    Beyond Memory Loss: Mastering the Management of Behavioral Symptoms in Dementia
    2 per page

    LAW: Call 1-800-Get-Cash Fast: Drug-Related Advertisements about Litigation-6 per page
    LAW: Call 1-800-Get-Cash Fast: Drug-Related Advertisements about Litigation
    -2 per page

     

    CE FINALE SCHEDULE/TOPICS/LEARNING OBJECTIVES

    7:30-8:00 a.m. – Registration and Check-In/Sign-In

    8:00-8:05 a.m. Opening Remarks- Philip Hritcko, Dean, School of Pharmacy

    8:05-8:10 a.m.Operational Instructions-Jeannette Y. Wick, Dir. OPPD

     

    8:10-9:10 a.m. – LAW: Medical-Legal Considerations of Aging Patients for Pharmacists
    Jennifer A. Osowiecki, RPh, JD, Cox & Osowiecki, LLC, Hartford, CT

    At the conclusion of this presentation, pharmacists will be able to:
    1. List at least three common medical-legal concerns associated with aging.

    2. Identify what constitutes elderly abuse or neglect and describe whether the pharmacist has a reporting obligation.

    3. Discuss the likelihood of polypharmacy and measures that pharmacists can employ to facilitate better medication management and compliance for elderly patients and their caregivers.

    0009-0000-24-042-L03-P     (0.1 CEU or 1 contact hour) (Application-based)

    9:15-10:15 a.m. Law: Seniors Self-Diagnosing and Treating: A Brave (and scary) New World

    Michael White, PharmD, FCCP, FCP, BOT Distinguished Professor and Chair of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT   

    At the conclusion of this presentation, pharmacists will be able to:
    1. Describe the reasons seniors are increasingly diagnosing and treating themselves with therapies
    2. Describe the legal and regulatory pathways that provide seniors access to therapies outside the drug supply chain
    3. Describe the ways that pharmacists can recommend dietary supplements that are free of adulterants and contaminants
    4. Describe the risks associated with self-treatment with dietary supplements, “peptides”, and counterfeit drugs

    0009-0000-24-044-L03-P (0.1 CEU or 1 contact hour) (Knowledge-based)

    10:20-11:20 a.m. – Balancing Safety and Efficacy: Addressing Medication Dilemmas in Older Adults

    Christina Polomoff, PharmD, BCACP, BCGP, FASCP, Population Health Clinical Pharmacist, Associate Clinical Professor, University of Connecticut School of Pharmacy, Storrs, CT

    At the conclusion of this presentation, pharmacists will be able to:
    1. Analyze pharmacokinetic and pharmacodynamic changes associated with aging
    2. Identify opportunities for deprescribing and medication management
    3. Use evidence-based tools and strategies to optimize medication regimens, applying deprescribing frameworks and decision aids in real-world geriatric care

    0009-0000-24-043-L01-P (0.1 CEU or 1 contact hour) (Application-based)

    11:25-12:25 p.m.  – Immunization: Our Best Shot – Tips and Tools to Vaccinate Older Adults

    At the conclusion of this presentation, pharmacists will be able to
    1.      RECOGNIZE appropriate vaccine recommendations for the older adult population

    2.      IDENTIFY potential barriers to vaccinations

    3.      ANALYZE current methods used to improve vaccination rates

    4.      DISCUSS ways to improve vaccine compliance in your patient population

    0009-0000-24-047-L06-P (0.1 CEU or 1 contact hour) (Application-based)

     

    12:25-12:45 p.m. – BREAK-light snacks will be served.

    12:45-1:45 p.m. – Opioids: Impact of Palliative Care on Total Pain in the Older Adult

    Megan Mitchell, PharmD, MS, Pharmacy Clinical Coordinator Pain Management and Palliative Care, University of Connecticut Healthcare, Farmington, CT         

    At the conclusion of this presentation, pharmacists will be able to:
    1. Describe Palliative Care and its importance in the healthcare system today
    2. Define the concept of “total pain” and the importance of whole person care in pain and symptom management
    3. Recognize the physiologic changes that occur with aging and how those impact pain and symptom management
    4. Determine the role of the pharmacist in total pain management in the older adult

    0009-0000-24-046-L08-P (0.1 CEU or 1 contact hour) (Application-based)

    1:50-2:50 p.m.  –Patient Safety: Cheers to the Beers: Unpacking the Latest Updates for Safer Prescribing
    Kelsey Giara, PharmD, Freelance Medical Writer, Pelham, NH

    At the conclusion of this presentation, pharmacists will be able to:
    1. Review the role of the Beers Criteria in reducing potentially inappropriate medication (PIM) use and enhancing patient safety in older adults
    2. Identify recent updates to the Beers Criteria and their implications for medication management in geriatric care
    3. Apply the updated Beers Criteria to real-world scenarios, optimizing medication selection and minimizing risks in older adult

    0009-0000-24-045-L05-P  (0.1 CEU or 1 contact hour (application-based)

    2:55-3:55 p.m.  – Beyond Memory Loss: Mastering the Management of Behavioral Symptoms in Dementia

    Kristin Waters, PharmD, BCPS, BCPP, Assistant Clinical Professor, UConn School of Pharmacy, Storrs, CT

    At the conclusion of this presentation, pharmacists will be able to:
    1. Identify clinical characteristics of the behavioral symptoms of dementia (BSD) including agitation, psychosis, and sleep disturbances
    2. Discuss medications currently used in the management of BSD along with emerging pharmacologic therapy options
    3. Determine the most appropriate pharmacologic treatment option for a patient with behavioral symptoms of dementia based on patient-specific factors

    0009-0000-24-048-L01-P  (0.1 CEU or 1 contact hour) (Application-based)

    4:00-5:00 p.m. –LAW: Call 1-800-Get-Cash Fast: Drug-Related Advertisements about Litigation
    Jeannette Y. Wick, RPh, MBA, Director Office of Professional Pharmacy Development, UConn School of Pharmacy, Storrs, CT

    At the conclusion of this presentation, pharmacists will be able to:
    1. Explain common terminology associated with commercials targeting older Americans
    2. Describe legal processes associated with lawsuits generated against companies that make products alleged to cause harm
    3. Discuss generalities in potential lawsuits associated with media promotion campaigns
    4. Identify areas where no information is available to provide good, valid answers for patients who ask questions

    0009-0000-24-049-L03-P (0.1 CEU or 1 contact hour) (Application-based)

     

    CE FINALE ENCORE WEBINARS AVAILABLE

    If you find you cannot make it to our LIVE EVENT on Friday, December 13th, you can participate in our ENCORE LIVE WEBINARS that will be streamed on the following dates:

    • Monday, December 16, 12:00 (Noon) – 1:00 pm – Seniors Self-Diagnosing and Treating: A Brave (and scary) New World
    • Monday, December 16, 7:00 pm – 8:00 pm – Patient Safety: Cheers to the Beers: Unpacking the Latest Updates for Safer Prescribing
    • Monday, December 16, 8:10 pm – 9:10 pm –  Immunization:  Our Best Shot – Tips and Tools to Vaccinate Older Adults
    • Tuesday, December 17, 12:00 (Noon) – 1:00 pm – Opioids: Impact of Palliative Care on Total Pain in the Older Adult
    • Tuesday, December 17, 7:00 pm-8:00 pm – LAW: Call 1-800-Get-Cash Fast: Drug-Related Advertisements about Litigation
    • Wednesday, December 18, 12:00 pm-1:00 pm – Beyond Memory Loss: Mastering the Management of Behavioral Symptoms in Dementia

    Registration Information

    Online: https://ce.pharmacy.uconn.edu/henry-a-palmer-ce-finale/

    A continuous class schedule format will be used.  This format does not include breaks but does include a 20 minute lunch period.

    Refunds and Cancellations:  The registration fee, less a $75 processing fee, is refundable for those who cancel their registration three (3) days prior to the program (by December 10) After that time, no refund is available.

    Location: The Henry A. Palmer C.E. Finale will be held both virtually or in-person. You must sign in to the Webex link at the designated time using the link in your confirmation email if you decide to participate virtually.

    Continuing Education Units

      Logo for the Accreditation Council for Pharmacy Education

      The University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Statements of Credit will be awarded at CE Finale based on full sessions attended and completed online evaluations.  Pharmacists can earn up to 8 contact hours (0.80 CEU) three of which are Law credits, and one is an Immunization credit, one is a Patient Safety credit and one is an Opioid credit.

      Please Note:  Pharmacists who wish to receive credit for the presentations MUST ACCURATELY complete the registration and online evaluations within 45 days of the live program (January 27, 2025).  Participants are accountable for their own continuing education requirements for license renewal and are required to follow up with joanne.nault@uconn.edu to resolve a discrepancy in a timely manner. PLEASE CHECK YOUR CPE MONITOR PROFILE within 3 days of submission to assure that your credits have been properly uploaded.  Requests for exceptions will be handled on a case-by-case basis and may result in denial of credit.

      Activity Support:  There is no funding for this program.

       

       

      Guideline-Driven Treatment for Mental Illnesses and Substance Abuse Disorders

      About this Course

      Pharmacists possess the training and skills necessary to administer certain long-acting injectable (LAI) medications used in the management of mental illnesses and substance use disorders. Through collaborative practice agreements, pharmacists can administer Long Acting Injectables in almost every state. In some states, including the state of Connecticut, this occurs via collaborative agreements, and necessary injection and disease state training.  Administration of these medications by pharmacists can increase accessibility of care for patients.

      UConn has developed web-based continuing pharmacy education activity to enhance pharmacists’ skills and help them make sound clinical decisions about long acting injectables administration. This course includes eight hours of CPE (or eight hours of credit), required by the State of Connecticut.  Successful completion of these eight hours (with four activities consisting of three hours online pre-requisite work and five hours of LIVE CE) will earn the pharmacist a Certificate in Long-Acting Injectables of Psychotropic Medication.

      The three activities below are available separately for $17/hour each, or as pre-requisites for the entire Long-Acting Injectable Psychotropic Medication Pharmacist Certificate Training Program at $299 which includes both the prerequisites and the full day of LIVE training.

      Target Audience

      Pharmacists who are interested in administering long acting injectable psychotropic medications to their patients.

      This activity is NOT accredited for technicians.

      Pharmacist Learning Objectives

      At the end of this application-based continuing education activity, the learner will be able to:

      Describe first- and second-line treatment options for the following disease states:

      ·        Schizophrenia

      ·        Bipolar disorder

      ·        Alcohol use disorder

      ·        Opioid use disorder

       

      Identify where long-acting injectable medications fit into treatment guidelines for each disorder

       

      Apply clinical treatment guidelines to select optimal pharmacologic treatment for a patient diagnosed with these disorders

      Release Date

      Released:  11/15/2023
      Expires:  11/15/2026

      Course Fee

      $17

      ACPE UAN

      0009-0000-23-051-H01-P

      Accreditation Hours

      1.0 hours of CE

      Session Code

      23LA51-VXT88

      Bundle Options

      If desired, pharmacists can register for the entire Long-Acting Injectable Psychotropic Medication Pharmacist Certificate Training Program

      or for the individual activities.   The Certificate consists of three activities in our online selection, and a 5 hour LIVE activity.

      You may register for individual topics at $17/CE Credit Hour, or for the Entire LAIA Certificate at $299.00 which includes 5 hours of LIVE CE and the 3 online pre-requisites listed below.

      You must register for ALL 4 activities to receive the bundled pricing of $299.00

      Accreditation Statement

      ACPE logo

      The University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit 1.0 hours (or 0.1 CEUS) for the online activity ACPE #0009-0000-23-051-H01-P will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

      Grant Funding

      There is no grant funding for this activity.

      Requirements for Successful Completion

      To receive CE Credit go to Blue Button labeled "take Test/Evaluation" at the top of the page.

      Type in your NABP ID, DOB and the session code for the activity.  You were sent the session code in your confirmation email.

      Faculty

      Kristin Waters, PharmD, BCPS, BCPP,
      Assistant Clinical Professor
      UConn School of Pharmacy
      Storrs, CT

      Faculty Disclosure

      In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

      Dr. Waters is a consultant with Janssen Pharmaceuticals. She will discuss all drugs without bias. All financial interests with ineligible companies (as noted) have been mitigated.

      Disclaimer

      This activity may contain discussion of off label/unapproved use of drugs. The content and views presented in this educational program are those of the faculty and do not necessarily represent those of the University of Connecticut School of Pharmacy. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

      Program Content

      Program Handouts

      Post Test Evaluation

      View Questions for Mental Illness and Substance Use Disorders: Background

      Additional Courses Available for Long Acting Injectable Training

       

      Mental Illness and Substance Use Disorders: Background - 1 hour

      Long-Acting Injectable Medication Products– 1 hour

       

      Long-Acting Injectable Medication Products

      About this Course

      Pharmacists possess the training and skills necessary to administer certain long-acting injectable (LAI) medications used in the management of mental illnesses and substance use disorders. Through collaborative practice agreements, pharmacists can administer Long Acting Injectables in almost every state. In some states, including the state of Connecticut, this occurs via collaborative agreements, and necessary injection and disease state training.  Administration of these medications by pharmacists can increase accessibility of care for patients.

      UConn has developed web-based continuing pharmacy education activity to enhance pharmacists’ skills and help them make sound clinical decisions about long acting injectables administration. This course includes eight hours of CPE (or eight hours of credit), required by the State of Connecticut.  Successful completion of these eight hours (with four activities consisting of three hours online pre-requisite work and five hours of LIVE CE) will earn the pharmacist a Certificate in Long-Acting Injectables of Psychotropic Medication.

      The three activities below are available separately for $17/hour each, or as pre-requisites for the entire Long-Acting Injectable Psychotropic Medication Pharmacist Certificate Training Program at $299 which includes both the prerequisites and the full day of LIVE training.

      Target Audience

      Pharmacists who are interested in administering long acting injectable psychotropic medications to their patients.

      This activity is NOT accredited for technicians.

      Pharmacist Learning Objectives

      At the end of this application-based continuing education activity, the learner will be able to:

      Compare and contrast among different long-acting injectable (LAI) medications currently available for the

      treatment of schizophrenia, bipolar disorder and substance use disorders including:

      ·        Dosing

      ·        Generic and brand names

      ·        Adverse effects

      ·        Administration schedule

      ·        Overlap with oral medications

      ·        FDA-approved indications

      Release Date

      Released:  11/15/2023
      Expires:  11/15/2026

      Course Fee

      $17

      ACPE UAN

      0009-0000-23-052-H01-P

      Accreditation Hours

      1.0 hours of CE

      Session Code

      23LA52-WXT36

      Bundle Options

      If desired, pharmacists can register for the entire Long-Acting Injectable Psychotropic Medication Pharmacist Certificate Training Program

      or for the individual activities.   The Certificate consists of three activities in our online selection, and a 5 hour LIVE activity.

      You may register for individual topics at $17/CE Credit Hour, or for the Entire LAIA Certificate at $299.00 which includes 5 hours of LIVE CE and the 3 online pre-requisites listed below.

      You must register for ALL 4 activities to receive the bundled pricing of $299.00

      Accreditation Statement

      ACPE logo

      The University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit 1.0 hours (or 0.1 CEUS) for the online activity ACPE #0009-0000-23-052-H01-P will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

      Grant Funding

      There is no grant funding for this activity.

      Requirements for Successful Completion

      To receive CE Credit go to Blue Button labeled "take Test/Evaluation" at the top of the page.

      Type in your NABP ID, DOB and the session code for the activity.  You were sent the session code in your confirmation email.

      Faculty

      Kristin Waters, PharmD, BCPS, BCPP,
      Assistant Clinical Professor
      UConn School of Pharmacy
      Storrs, CT

      Faculty Disclosure

      In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

      Dr. Waters is a consultant with Janssen Pharmaceuticals. She will discuss all drugs without bias. All financial interests with ineligible companies (as noted) have been mitigated.

      Disclaimer

      This activity may contain discussion of off label/unapproved use of drugs. The content and views presented in this educational program are those of the faculty and do not necessarily represent those of the University of Connecticut School of Pharmacy. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

      Program Content

      Program Handouts

      Post Test Evaluation

      View Questions for Long-Acting Injectable Medication Products

      Additional Courses Available for Long Acting Injectable Training

       

      Mental Illness and Substance Use Disorders: Background - 1 hour

      Guideline-Driven Treatment for Mental Illnesses and Substance Abuse Disorders– 1 hour

       

      Mental Illness and Substance Use Disorders: Background

      About this Course

       

       

      Pharmacists possess the training and skills necessary to administer certain long-acting injectable (LAI) medications used in the management of mental illnesses and substance use disorders. Through collaborative practice agreements, pharmacists can administer Long Acting Injectables in almost every state. In some states, including the state of Connecticut, this occurs via collaborative agreements, and necessary injection and disease state training.  Administration of these medications by pharmacists can increase accessibility of care for patients.

      UConn has developed web-based continuing pharmacy education activity to enhance pharmacists’ skills and help them make sound clinical decisions about long acting injectables administration. This course includes eight hours of CPE (or eight hours of credit), required by the State of Connecticut.  Successful completion of these eight hours (with four activities consisting of three hours online pre-requisite work and five hours of LIVE CE) will earn the pharmacist a Certificate in Long-Acting Injectables of Psychotropic Medication.

      The three activities below are available separately for $17/hour each, or as pre-requisites for the entire Long-Acting Injectable Psychotropic Medication Pharmacist Certificate Training Program at $299 which includes both the prerequisites and the full day of LIVE training.

      Target Audience

      Pharmacists who are interested in administering long acting injectable psychotropic medications to their patients.

      This activity is NOT accredited for technicians.

      Pharmacist Learning Objectives

      At the end of this application-based continuing education activity, the learner will be able to:

      Describe the prevalence, pathophysiology, clinical features, and diagnostic criteria of:

      ·        Schizophrenia

      ·        Bipolar disorder

      ·        Substance use disorders

       

      Differentiate between signs and symptoms of these disorders

      Release Date

      Released:  11/15/2023
      Expires:  11/15/2026

      Course Fee

      $17

      ACPE UAN

      0009-0000-23-050-H01-P

      Accreditation Hours

      1.0 hours of CE

      Session Code

      23LA50-TXJ44

      Bundle Options

      If desired, pharmacists can register for the entire Long-Acting Injectable Psychotropic Medication Pharmacist Certificate Training Program

      or for the individual activities.   The Certificate consists of three activities in our online selection, and a 5 hour LIVE activity.

      You may register for individual topics at $17/CE Credit Hour, or for the Entire LAIA Certificate at $299.00 which includes 5 hours of LIVE CE and the 3 online pre-requisites listed below.

      You must register for ALL 4 activities to receive the bundled pricing of $299.00

      Accreditation Statement

      ACPE logo

      The University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit 1.0 hours (or 0.1 CEUS) for the online activity ACPE #0009-0000-23-050-H01-P will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

      Grant Funding

      There is no grant funding for this activity.

      Requirements for Successful Completion

      To receive CE Credit go to Blue Button labeled "take Test/Evaluation" at the top of the page.

      Type in your NABP ID, DOB and the session code for the activity.  You were sent the session code in your confirmation email.

      Faculty

      Kristin Waters, PharmD, BCPS, BCPP,
      Assistant Clinical Professor
      UConn School of Pharmacy
      Storrs, CT

      Faculty Disclosure

      In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

      Dr. Waters is a consultant with Janssen Pharmaceuticals. She will discuss all drugs without bias. All financial interests with ineligible companies (as noted) have been mitigated.

      Disclaimer

      This activity may contain discussion of off label/unapproved use of drugs. The content and views presented in this educational program are those of the faculty and do not necessarily represent those of the University of Connecticut School of Pharmacy. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

      Program Content

      Program Handouts

      Post Test Evaluation

      View Questions for Mental Illness and Substance Use Disorders: Background

      Hour 1: Mental Illness and Substance Use Disorders: Background

      1. A 38-year-old patient with an unknown psychiatric history is dropped off at the emergency department by police after being found wandering the streets and knocking on doors at random. The patient admits that they believe they are being monitored by the FBI and that “the mafia” wants to recruit them as a spy. The patient is observed having a conversation with themselves while alone in the examination room.

      Which of the following positive symptoms is the patient likely experiencing?
      A. Psychosis and auditory hallucinations
      B. Auditory hallucinations and delusions
      C. Delusions and anhedonia
      D. Paranoia and agitation

      2. Which of the following is the correct term for fixed, false beliefs that patients with schizophrenia may experience?
      A. Delusions
      B. Hallucinations
      C. Disorganized speech
      D. Catatonia

      3. A patient with schizophrenia has experienced both positive and negative symptoms for several years. They are now presenting with signs of mania, including pressured speech and grandiosity. Which of the following is true?
      A. The patient’s diagnosis will likely change to schizoaffective disorder, bipolar type
      B. The patient’s diagnosis will likely change to schizoaffective disorder, depressive type
      C. The patient will now be diagnosed with schizophrenia and bipolar disorder
      D. The patient will now be diagnosed with schizophrenia and major depressive disorder

      4. Which of the following is true about bipolar disorder?
      A. The most common time that patients are diagnosed is during childhood
      B. Most patients are initially diagnosed with schizophrenia
      C. It has a higher mortality rate than major depressive disorder
      D. Type II bipolar disorder is associated with more severe episodes of mania than type I

      5. Most patients with bipolar disorder spend the majority of their time in which mood phase?
      A. Mania
      B. Depression
      C. Hypomania
      D. Euthymia

      6. A patient with bipolar disorder presents to their outpatient provider and reports that they believe they are on the verge of a “breakthrough” and will soon become a world-famous author once their manuscript is published. They have recently stopped going to work and have been writing “all day and all night” for the past week. They also report spending thousands of dollars on a new computer so that they have “the best equipment” with which to write their manuscript.
      Which of the following symptoms of mania is the patient displaying?
      A. Grandiosity, decreased need for sleep, increased goal directed activity
      B. Flight of ideas, distractibility, grandiosity
      C. Disorganized thoughts, decreased need for sleep, flight of ideas
      D. Confusion, excessive spending, distractibility

      7. Patient NP was diagnosed with bipolar disorder, type II approximately 5 years ago. They have rarely missed work due to hypomanic symptoms, and are generally able to perform all day-to-day activities without impairment. Following a breakup, NP begins to display signs of grandiosity, flight of ideas, decreased sleep, and increased spending. They also begin to hear the voice of their ex-partner telling them that they are worthless.

      Which of the following is most appropriate?
      A. NP’s diagnosis should be changed to bipolar disorder type I
      B. NP’s diagnosis should remain the same
      C. NP’s diagnosis should be changed to schizoaffective disorder
      D. NP’s diagnosis should be changed to bipolar disorder, mixed type

      8. Which of the following is a risk factor for the development of a substance use disorder?
      A. Female gender
      B. Age > 65 years
      C. Co-occurring psychiatric disorder
      D. Parenthood

      9. Which type of opioid receptor contributes to the stimulation of the dopamine-related reward system?
      A. Mu-opioid receptor
      B. Kappa-opioid receptor
      C. Delta-opioid receptor
      D. Beta-opioid receptors

      Additional Courses Available for Long Acting Injectable Training

       

      Guideline-Driven Treatment for Mental Illnesses and Substance Abuse Disorders– 1.0 hour

      Long-Acting Injectable Medication Products– 1 hour

       

      Law: Off-Label Drug Use and The Pharmacist’s Role

      About this Course

      This course is a recorded (home study version) of the CE Finale Encore Webinars.

       

      Learning Objectives

      Upon completion of this application based CE Activity, a pharmacist will be able to:

      ·       Differentiate critical state and federal personnel law
      ·       Explain common personnel laws and issues with their implementation
      ·       List pharmacy-related laws most likely to be violated
      ·       Identify ways to improve adherence to laws

      Release and Expiration Dates

      Released:  December 21, 2021
      Expires:  December 17, 2024

      Course Fee

      $15 Pharmacist

      ACPE UAN

      0009-0000-21-055-H03-P

      Session Code

      21RW55-JXT85

      Accreditation Hours

      1.0 hours of CE

      Additional Information

       

      How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

      Accreditation Statement

      The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-21-055-H03-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

      Grant Funding

      There is no grant funding for this activity.

      Faculty

      Jeannette Y. Wick, RPh, MBA, FASCP
      Asst. Director OPPD
      University of Connecticut School of Pharmacy
      Storrs, CT

      Faculty Disclosure

      In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

      • Jeannette  Wick has no relationships with ineligible companies

      Disclaimer

      The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

      CONTENT

      POST TEST

      1. How do federal and state law compare?
      A. Most states use a model that mimics federal system
      B. State law trumps any federal law in explicit conflict
      C. The law that affords the fewest rights always prevails

      2. An employee believes she has a discrimination case against her employer. She does her research and learns she is unlikely to win. What type of discrimination has she alleged?
      A. Retaliation
      B. Color
      C. Race

      3. Why is the OSHA “look-back” period important once a pharmacy is cited for a violation?
      A. Repeat citations for the same violation during the next five years can cost up to $70,000 each
      B. OSHA can fine employers if employees allege violations in previous five years without proof
      C. Should an employee death or injury occur within five years, OSHA will shutter the business.

      4. Which of the following questions can reduce risk and increase employee satisfaction in your workplace when an employee files a complaint or grievance?
      A. Did you complain about this at your last job?
      B. What exactly is your problem?
      C. What relief are you seeking?

      5. What can an employer use as an affirmative defense if an employee files a discrimination complaint?
      A. Demonstrate the plaintiff’s performance was better than other employees’
      B. Provide detailed records of complaint filed by clients/patients/customers
      C. Show documentation that the plaintiff was an acceptable team player

      Handouts

      VIDEO

      Law: Psychedelic Drugs: Can They Make the “Trip” to the Pharmacy Shelf?-RECORDED WEBINAR

      The Arthur E. Schwarting Symposium is an educational conference focused on pharmacy practice for pharmacists in many settings.

      This year's sympoisum had an overall topic of pharmcogenesy which was a favorite area of Dean Schwarting's.  This presentation is a Law CE revolving around psychodelic drugs used to treat Mental Health Disorders.

      Learning Objectives

      1. Review the development of the knowledge of the effects of psychedelic drugs and their potential use in
      psychiatry, with an emphasis on psilocybin.
      2. Characterize the traditional legal classification of psychedelic drugs and modern reconsideration of their legal
      status.
      3. Describe efforts at the state level to expand the medical use of psychedelic drugs.

      Session Offered

      Released:  April 27, 2023
      Expires:  April 27, 2026

      Course Fee

      $17 Pharmacist

      ACPE UAN Codes

       0009-0000-23-011-H03-P

      Session Code

      23RW11-TXJ88

      Accreditation Hours

      1.0 hours of CE

      Accreditation Statement

      The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive 1.0 CE Hour  for completing the activity  (ACPE UAN 0009-0000-22-017-H03-P), passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

      Grant Funding

      There is no grant funding for this activity.

      Faculty

      Gerald Gianutsos, PhD, JD,
      Professor Emeritus
      University of Connecticut School of Pharmacy
      Storrs, CT 

      Faculty Disclosure

      Dr. Gianutsos has no financial relationships with any ineligible company associated with this presentation.

      Disclaimer

      The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

      Content

      Handouts

      Post Test Pharmacist

      Schwarting Webinar 2023 Post-Test

       

        1. Review the development of the knowledge of the effects of psychedelic drugs and their potential use in psychiatry, with an emphasis on psilocybin.
        2. Characterize the traditional legal classification of psychedelic drugs and modern reconsideration of their legal status.
        3. Describe efforts at the state level to expand the medical use of psychedelic drugs.

       

      The tryptamine class of psychedelic drugs (e.g., LSD, psilocybin) produce their psychedelic/therapeutic effects by acting as agonists of a neurotransmitter in the CNS. What is the relevant neurotransmitter system?

       

      1. Serotonin
      2. Dopamine
      3. Glutamate

       

       

      The FDA granted “breakthrough therapy” designation to psilocybin for treatment of a specific condition. What condition is it?

      1. Schizophrenia
      2. Treatment resistant depression
      3. Post traumatic stress disorder

       

       

       

      Which feature distinguishes a C-I drug from other controlled substances?

      1. High potential for abuse, especially among hi-riskpopulations
      2. Lack of accepted safety for use under medical supervision
      3. No currently accepted medical use in treatment in the United States

       

       

      Which state was the first to approve the use of psilocybin for medical use?

      1. California
      2. Oregon
      3. Maryland

       

       

      A patient considering psilocybin treatment for a psychiatric disorder asks you for advice; he is specifically interested in disadvantages of this type of therapy. What do you tell him?

      1. Use of psychedelic therapy is time-and resource-intensive
      2. Requires multiple treatments with a slow onset of activity
      3. There is a high risk of autonomic side effects and addiction

       

       

      In the state where medical use of psilocybin was first approved, which of the following statements describes its availability?

      1. Psilocybin can be purchased at retail outlets including pharmacies
      2. Psilocybin is available from any therapist throughout the state
      3. Psilocybin is only available in state licensed clinics

       

      Patient Safety: Pharmacy Metrics-Recorded Webinar

      About this Course

      This course is a recorded (home study version) of the Pharmacy Metrics Webinar

       

      Learning Objectives

      Upon completion of this application based CE Activity, a pharmacy technician will be able to:

      • Describe the importance of pharmacy metrics for efficient operation.
      • Define pharmacy metrics in various settings.
      • Describe how team members can effectively contribute to the workplace

      Release and Expiration Dates

      Released:  September 15, 2023
      Expires:  September 15, 2026

      Course Fee

      $4  Pharmacy Technician

      ACPE UAN

      0009-0000-23-026-H05-T

      Session Code

      20YC63-BCX86

      Accreditation Hours

      1.0 hours of CE

      Additional Information

       

      How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

      Accreditation Statement

      The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-23-026-H05-T, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

      Grant Funding

      There is no grant funding for this activity.

      Faculty

      Sara Miller, PharmD
      CVS Pharmacist
      Foxboro, MA

      Kyra Durfee, PharmD Candidate 2022
      UConn School of Pharmacy
      Storrs, CT

      Gabriella Scala, PharmD Candidate 2022
      UConn School of Pharmacy
      Storrs, CT 

      Faculty Disclosure

      In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

      • Sara Miller, Kyra Durfee and Gabriela Scala have no relationships with ineligible companies and therefore nothing to disclose.

      Disclaimer

      The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

      Content

      Post Test

      1. Which of the following is NOT a use for metrics in pharmacies?
      A. Quantify workflow
      B. Exhaust staff
      C. Establish comparators

      2. Patient-centered metrics are based on which of the following?
      A. Profits
      B. Public health initiatives
      C. Patient complaints

      3. _____ is a metric used to assess productivity.
      A. Time-to-fill
      B. Rate of medication errors
      C. Out-of-stock prescriptions

      4. Which of the following is a good way to reach vaccination metrics?
      A. Letting the patient contact the pharmacy about vaccinations
      B. Reminding patients of vaccinations at the register
      C. Relying on advertising to encourage patients

      5. What does SMART goals, a great way to develop an approach to improve metrics, stand for?
      A. Specific, Measurable, Achievable, Relevant, Time-Bound
      B. Specific, Measurable, Achievable, Resourceful, Time-Bound
      C. Specific, Measurable, Accurate, Reasonable, Time-Bound

      6. What is the most important skill in the workplace when tackling metrics?
      A. Speed
      B. Communication
      C. Knowledge

      7. Many metrics focus on efficiency. What other consideration is crucial?
      A. Type of pharmacy
      B. Patient safety
      C. Workload or volume

      8. Select the statement that is TRUE:
      A. Metrics usually refer to a general aspect of pharmacy tasks, so they are the same in community and clinical settings.
      B. While metrics often refer to a general aspect of pharmacy tasks, they can vary greatly between community and clinical settings.
      C. While metrics often refer to a general aspect of pharmacy tasks, pharmacies should stay away from standard metrics and develop new approaches.

      9. Super Tech is worried about her pharmacy’s time-to-fill metric. Wonder Pharmacist is focused on inventory metrics. Three months go by and they haven’t made good progress on either. Why?
      A. They are working alone on each metric, but need to be working together.
      B. It’s not possible to work on two metrics at the same time.
      C. Improving time-to-fill metrics will adversely influence inventory metrics.

      10. Which of the following activity falls heavily on pharmacy technicians and contributes heavily to pharmacy metrics in the community setting?
      A. Vaccinations
      B. Insurance and billing
      C. In-person patient interaction

      Handouts

      VIDEO

      NAPLEX Calculation Review LIVE Event-2025

      Are you studying for the NAPLEX EXAM?

      NAPLEX Pharmacy Calculations Review 2025

      Live Event-THIS WILL BE A LIVE IN-PERSON Event (no streaming)

      Date:  Friday, May 16, 2025
      Where:  Pharmacy Biology Building (PBB) Room 131
      Time:  8:30 am – 4:30 pm
      Cost:  $0

      You MUST Register (even though there is no fee)

      There is a fee for parking in the North Garage

      Typical Schedule:

      Friday

      8:30-9:00     Check in and Presentation of Program and Review
      9:00- 10:00  Diagnostic Test Administration
      10:00-10:45  Review Answers t0 Diagnostic Test
      10:45-11:00   Break
      11:00-12:00   Students work on problem sets
      12:00-1:00     Lunch
      1:00-4:30       NAPLEX Calculations workshop

      Lunch will be provided, please contact Alicia Scolaro at alicia.scolaro@uconn.edu with any dietary restrictions